IGF-1 is an independent risk factor for anemia in diabetic pre-dialysis patients

Korean Journal of Internal Medicine

Volumn 22, Issue 3, 2007, Pages 186-191

  Kim, Do Hyoung ^a   Kim, Tae Young ^a   Kim, Sun Min ^a   Yoo, Soo Jeong ^a   Oh, Dong Jin ^a   Yu, Suk Hee ^a,b  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

ACE inhibitor; Anemia; Diabetes mellitus; Insulin like growth factor I; Kidney failure

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON; LACTATE DEHYDROGENASE; LEPTIN; PARATHYROID HORMONE; SOMATOMEDIN C;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD ANALYSIS; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; KIDNEY FAILURE; KOREA; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SEX DIFFERENCE;

EID: 36549073809     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2007.22.3.186     Document Type: Article

References (33)

1. Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Cardiac disease in diabetic end-stage renal disease. Diabetologia 40:1307-1312, 1997
2. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy Diabetes Care 24:495-499, 2001
3. Ishimura E, Nishizawa Y, Okuno S, Matsumoto N, Emoto M, Inaba M, Kawagishi T, Kim CW, Morii H. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 11:83-86, 1998
4. European Best Practice Guidelines for the management of anemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 14(Suppl 5):1-50, 1999
5. Esohbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
6. Spivak JL. Serum immunoreactive erythropoietin in health and disease. J Perinat Med 23:13-17, 1995
7. Adamson JW, Eschbach J, Finch CA. The kidney and erythropoiesis. Am J Med 44:725-733, 1968
8. Winearls CG. Historical review on the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dial Transplant 10(Suppl 2):3-9, 1995
9. Eschbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis 11:203-209, 1988
10. Danielson B. R HuEPO hyporesponsiveness: - who and why? Nephrol Dial Transplant 10(Suppl 2):69-73, 1995
11. Drueke TB. R HuEPO hyporesponsiveness: - who and why? Nephrol Dial Transplant 10(Suppl 2):62-68, 1995
12. Chaplin H Jr, Mollison PL. Red cell life span in nephritis and in hepatic cirrhosis. Clin Sci 12:351-360, 1953
13. Fukushima Y, Nakamoto Y, Miura AB, Miyagata S, Tsuchida S. The inhibitory factors of hematopoiesis in chronic hemodialysis patients treated with recombinant human erythrepoietin. Tohoku J Exp Med 161:217-225, 1990
14. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial N Engl J Med 316:73-78, 1987
15. Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human penpheral blood in an improved serum-free medium: role of insulin like growth factor 1. Blood 78:2823-2833, 1991
16. Deicher R, Horl WH. Hormonal adjuvants for the treatment of renal anemia. Eur J Clin Invest 35(Suppl 3):75-84, 2005
17. Axelsson J, Qureshi AR, Heimburger O, Lindholm B, Stenvinkel P, Barany P. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kid Dis 46:628-634. 2005
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-470, 1999
19. White KE, Bilous RW. Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type I disease. J Am Soc Nephrol 11:1667-1673, 2000
20. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinlar S, Simpson RL, Snapinn SM, Toto R. The risk of developing end stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 63:1499-1507. 2003
21. Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoletin. N Engl J Med 229:611-615, 1993
22. Ghidanda G, Cotroneo P, Todaro L, Pitocco O, Manto A, Storti S, Caputo S, Ricerca BM. Erythropoietin depletion and anemia in diabetes mellitus. Diabet Med 17:410, 2000
23. Ranmani Jourdheuil D, Mourayre Y, Vague P, Boyer J, Juhan-Vague I. In vivo insulin effect on ATPase activities in erythrocyte membrane from insulin dependent diabetics. Diabetes 36:991-995, 1987
24. Bryszewska M, Watala C, Torzecka W. Changes in fluidity and composition of erythrocyte membranes and in composition of plasma lipids in type I diabetes. Br J Haematol 62:111-116, 1986
25. Sonksen PH, Russell-Jones O, Jones RH. Growth hormone and diabetes mellitus. a review of sixty-three years of medical research and a glimpse into the future? Horm Res 40:68-79, 1993
26. Thraikill KM. Insulin-like growth factor-1 in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility Diabetes Technol Ther 2:69-80, 2000
27. Garay-Sevilla ME, Nava LE, Malacara JM, Wróbel K, Wróbel K, Perez U. Advanced glycosylation end products, insulin-like growth factor-1 and IGF-binding protein-3 in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 16:106-113, 2000
28. Brox AG, Zhang F, Guyda H, Gagnon RF, Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse. Kidney Int 50:937-943, 1996
29. Shih LY, Huang JY, Lee CT. Insulin-like growth factor 1 plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol 10:315-322. 1999
30. Onoyama K, Sanoi T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 13(Suppl 3):S27-S30, 1989
31. Fyhrquist F, Karppinen K, Honkanen T, Saijonmaa O, Rosenlof K. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 226:257-260, 1989
32. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant patients treated for hypertension. Am J Kidney Dis 17:199-205, 1991
33. Morrone LF, Di Paolo S, Logoluso F, Schena A, Stallone G, Giorgino F, Schena FP. Interference of angiotensin-converting inhibltors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 64:913-918, 1997